Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $67.00 Price Target at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price increased by Cantor Fitzgerald from $63.00 to $67.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $48.75 on Thursday. Supernus Pharmaceuticals has a 1 year low of $32.20 and a 1 year high of $59.68. The stock has a market cap of $2.83 billion, a P/E ratio of -95.59, a P/E/G ratio of 1.08 and a beta of 0.54. The stock has a 50-day simple moving average of $47.10 and a 200-day simple moving average of $49.50.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SUPN. State Street Corp increased its stake in shares of Supernus Pharmaceuticals by 1.4% during the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after acquiring an additional 31,668 shares during the period. Geode Capital Management LLC boosted its holdings in Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after purchasing an additional 62,875 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in Supernus Pharmaceuticals by 12.7% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after purchasing an additional 162,905 shares in the last quarter. Stephens Investment Management Group LLC increased its position in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after purchasing an additional 61,120 shares during the period. Finally, Woodline Partners LP increased its position in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after purchasing an additional 490,835 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.